COPD drug Daxas fails to obtain FDA panel's endorsement

04/7/2010 | Google · Reuters

An FDA panel voted 10-5 against recommending the approval of Daxas, Nycomed and Forest Laboratories' drug for chronic obstructive pulmonary disease, citing the product's dangerous side effects. A Forest official said the drugmaker is "disappointed" by the vote but thinks the committee's concerns "are clearly negotiable with the agency."

View Full Article in:

Google · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX